Wolffenbuttel, B. H. R.Van Gaal, L.Duran-Garcia, S.Han, J.2023-02-122023-02-122016-08-011462-8902http://hdl.handle.net/10668/18985This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (35 kg/m(2)) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30-week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed. Glycated haemoglobin (HbA1c) reductions were significant (penAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/body mass indexexenatide twice dailytype 2 diabetesPeptide-1 receptor agonistBasal insulinBolus insulinSafetyLiraglutideManagementDegludecresearch articleopen access10.1111/dom.126691463-1326https://doi.org/10.1111/dom.12669379904300011